The global intravenous (IV) iron drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market includes the growing prevalence of chronic kidney disease (CKD), inflammatory bowel disease (IBD), and cancer around the globe, which has led to an increase in the need for intravenous iron drugs for the treatment of subsequent iron deficiency anemia (IDA). In addition, approval and launch of novel formulations and strategic initiatives undertaken by key players to improve access to intravenous iron drugs are further expected to support market growth. Increasing prevalence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, cancer, liver disorders, thyroid diseases, and inflammatory bowel diseases, is another factor that accelerates the growth of the global intravenous (IV) iron drugs market. Some of the most common forms of anemia include iron and vitamin deficiency, a plastic, hemolytic, and sickle cell. Some of the common causes of anemia include iron, vitamin A and B12, and folate deficiencies. Infectious diseases such as tuberculosis, parasitic infections, malaria, and HIV are major causes of anemia across the globe. 

Furthermore, other advantages of intravenous iron drugs include the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis. These adverse effects are, hence, anticipated to facilitate the switch to intravenous iron drugs, increasing the uptake of the same during the forecast period. The global intravenous iron drugs market is highly competitive owing to the presence of several global players. Market participants such as Daiichi Sankyo Company, Ltd. and Vifor Pharma Management Ltd. accounted for the majority of market revenue share in 2020. They adopt different growth strategies such as new product development and expansion of geographical reach, to capture large share in the market. For instance, in September 2020, the company announced the establishment of its wholly-owned subsidiary Daiichi Sankyo Vietnam Co., Ltd. This initiative was undertaken in order to enhance the company’s business in Asia. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Vifor Pharma Management Ltd., Daiichi Sankyo Company, Ltd., and Sanofi S.A., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Intravenous (IV) Iron Drugs Market Report by Segment

By Product Type

• Iron Dextran

• Ferric Carboxymaltose

• Iron Sucrose

• Ferric Gluconate

By Application

• Cancer

• Nephrology

• Gastroenterology and Obstetrics

• Gynecology

• Cardiology

• Others

Global Intravenous (IV) Iron Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa